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PDR
proliferative diabetic retinopathy PEDF pigment epithelium-derived factor VEGF vascular endothelial growth factor To the Editor: Intraocular neovascularisation develops in many ischaemic retinal diseases, e.g. diabetic retinopathy, ischaemic retinal vein occlusion and retinopathy of prematurity. The new vessels are fragile and often rupture, leading to vitreous haemorrhage, tractional retinal detachment, neovascular glaucoma and subsequent vision decrease. The formation of new vessels is dependent on a local balance of stimulators and inhibitors of angiogenesis [1] . Among the stimulators, vascular endothelial growth factor (VEGF) has been shown to play a major role in mediating active neovascularisation in patients with diabetic retinopathy [2] . In addition, several studies have shown that the concentration of VEGF in the intraocular fluids was significantly elevated in eyes with proliferative diabetic retinopathy (PDR) [3] [4] [5] . On the other hand, pigment epithelium-derived factor (PEDF) is a potent inhibitor of angiogenesis, and lower levels of PEDF have been found in the vitreous of eyes with active diabetic retinopathy [4] . It has also been shown that the vitreous level of endostatin, another inhibitor of angiogenesis, is correlated with the level of VEGF and that endostatin is produced in the fibrovascular membrane of eyes with PDR [5] .
Vasohibin-1, a novel angiogenesis inhibitor, is mainly produced in endothelial cells and is induced by stimulation with VEGF or fibroblast growth factor 2. Vasohibin-1 selectively affects endothelial cells and inhibits angiogenesis [6] . We therefore hypothesised that vasohibin-1 is present in the vitreous of eyes with PDR and is associated with the vitreous level of VEGF. To examine this hypothesis, we measured the vitreous levels of vasohibin-1 and VEGF in 49 samples from 46 patients. This study was conducted in accordance with the tenets of the Declaration of Helsinki as revised in 2000 and was carried out with the approval of the Institutional Review Board of Tohoku University. Informed consent was obtained from all patients after an explanation of the purpose and procedures of the study.
The level of VEGF, measured by ELISA, was significantly higher in the vitreous samples from patients with PDR↑ (584.0±641.5 ↑pg/ml ↑[mean±SD]; n=37) than in samples from control patients with idiopathic macular hole or idiopathic epiretinal membrane (19.61±19.80 pg/ml; n=12; p=0.004; Student's t test). Western blot analysis using antivasohibin-1 mouse monoclonal antibody showed a 42 kDa band and/or a 36 kDa band of different intensity levels in 34 (92%) of the 37 vitreous samples of patients with PDR (Fig. 1a) . No signal was detected in any control samples. To investigate the association between the vitreous levels of vasohibin-1 and VEGF, we determined the band intensity of the samples relative to that of given recombinant vasohibin-1 (100 fmol) using the publicly available ImageJ software (National Institutes of Health, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/). We observed a statistically significant correlation between the vitreous concentration of vasohibin-1 and VEGF in the 37 samples with PDR (r=0.469, p=0.005; Spearman correlation coefficient by rank test) (Fig. 1b) .
What is the source of the 42 kDa and 36 kDa forms of vasohibin-1 seen in the vitreous samples and detected by western blotting? An earlier study reported that the 36 kDa form was generated by processing the 42 kDa form and that both forms had anti-angiogenesis activity [7] . The forced production of vasohibin-1 in HUV-SV8 cells demonstrated that secreted vasohibin-1 is mostly the larger 42 kDa form and that the other major form (36 kDa) of the protein accumulates within the cells or pericellular milieu [7] . In our study, immunohistochemical analysis showed that vasohibin-1 was produced in the fibrovascular membranes of eyes with PDR (Fig. 1c,d ). We suggest that one of the sources of vasohibin-1 is the endothelial cells in the fibrovascular membranes. As the blood-retina barrier in eyes with PDR is damaged, we cannot completely exclude the possibility that the vasohibin-1 in the vitreous cavity was from the blood. However, the concentration of vasohibin-1 in the plasma for the samples available from patients with PDR was very low (1.8±2.6 fmol/ml [mean±SD]; n=7) and was not statistically correlated with that in the vitreous (r=0.259, p=0.54; Spearman correlation coefficient by rank test), suggesting that the vasohibin-1 in the vitreous is mostly derived from the intraocular tissues. It remains to be determined whether the production of vasohibin-1 in the retinas of eyes with PDR is upregulated and whether vasohibin-1 is secreted into the vitreous cavity, because vasohibin-1 is produced in retinal cells as well as endothelial cells in normal mouse retinas [8] .
Hypoxia induces VEGF, VEGF induces the production of vasohibin-1 in endothelial cells and vasohibin-1 inhibits angiogenesis as a negative feedback regulator [6] . On the other hand, hypoxia, as well as inflammatory cytokines (e.g. TNF-α and IL-1β, levels of which are increased in the vitreous of eyes with PDR), may reduce the VEGFstimulated induction of vasohibin-1 in endothelial cells [6] . Many growth factors play an important role in the complex pathogenesis of diabetic retinopathy, in which hypoxia triggers angiogenesis. The results of this study show that the vitreous level of vasohibin-1 was positively correlated with that of VEGF, which suggests that vaso- 6) and 100 fmol recombinant vasohibin-1 (control) were loaded in this representative western blot. b Correlation between the vitreous concentration of vasohibin-1 and VEGF (r=0.469, p=0.005; Spearman correlation coefficient by rank test). The band intensities in the western blots were determined by ImageJ software. Relative vasohibin-1 intensity was calculated as the ratio of sample band intensity to control band intensity. Sample band intensity represents the sum of the 42 and 36 kDa vasohibin-1 bands. Exposure time of western blot was fixed to 30 s before the bands were saturated. Western blot analyses were performed in duplicate for each sample. VEGF concentration in the vitreous fluid was measured by ELISA using a human VEGF immunoassay (R&D Systems, Minneapolis, MN, USA). c Expression of vasohibin-1 in the surgically removed fibrovascular membranes of eyes with PDR. Fibrovascular membrane contains many new vessels. Immunohistochemistry using anti-vasohibin-1 mouse monoclonal antibody showed signals in the endothelial cells (arrows). d Absorbed antibody was used for the controls; no significant signal was seen. Scale bars, 100 μm hibin-1 regulates retinal angiogenesis as an inhibitor. An intraocular injection of recombinant vasohibin-1 strongly suppressed retinal neovascularisation in mice with ischaemic retinopathy [9] , suggesting that vasohibin-1 could be a good candidate for development as a therapeutic agent for diabetic retinopathy, especially in terms of mechanisms different from those in anti-VEGF therapy.
